Pharma

Immuneering Appoints Leah R. Neufeld as Chief People Officer

Retrieved on: 
Thursday, October 20, 2022
People, U.S. Securities and Exchange Commission, Therapy, American, MEK, Growth, Intercept Pharmaceuticals, Leah, Johnson & Johnson, Human, Patient, Drug development, 3D, Psychology, Entrepreneurship, RAS, Johns Hopkins University, Jiangsu Hengrui Medicine, Cancer, American University, Acquisition, Industry, Eli Lilly, NPS, Chemistry, GLOBE, Human resources, Forward-looking statement, MAPK, Shire (pharmaceutical company), China Bio-Immunity Corporation, Risk, Pharmaceutical industry, Pharma, IND, The Immune Response Corporation

Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Key Points: 
  • Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.
  • Leah is a seasoned human resources leader with decades of experience in the life sciences industry.
  • Ms. Neufeld joins Immuneering from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China.
  • Prior to that, from 2015 through 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals.

Covis Pharma Reports on FDA Advisory Committee Hearing for Makena®

Retrieved on: 
Wednesday, October 19, 2022
Pharma, Risk, Reproduction, Obstetrics, CDER, Preterm birth, Organization, Regulation of tobacco by the U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Pregnancy, Patient, Advisory Committee, Dermatologic and Ophthalmic Drugs Advisory Committee, Food, Company, Francis Covi, Doctor of Philosophy, GLOBE, Hearing, Center, FDA, Pharmaceutical industry, Research

Covis respects the regulatory decision-making process and appreciated the opportunity to present our patient-focused study designs and data to the Center for Drug Evaluation and Research (CDER) at FDA and members of the Advisory Committee, said Covis CEO Michael Porter.

Key Points: 
  • Covis respects the regulatory decision-making process and appreciated the opportunity to present our patient-focused study designs and data to the Center for Drug Evaluation and Research (CDER) at FDA and members of the Advisory Committee, said Covis CEO Michael Porter.
  • We are also thankful for the viewpoints expressed by patients and organizations that see the importance of Makena and its generics.
  • As presented during the hearing, we believe that Makena is effective in a higher-risk patient population, said Raghav Chari, PhD, chief innovation officer at Covis.
  • Per the regulatory process, Makena remains approved and the product label remains unchanged at this time as the Company awaits a final decision by the FDA.

European Post Marketing Pharmacovigilance Training Course (November 2-4, 2022) - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Health, Pharmaceutical, European Medicines Agency, Communication, QA, EMA, Pharmacovigilance, Regulatory agency, Regulation, Quality management system, Company, QMS, PRAC, Legislation, Safety, KPI-driven code analysis, Compliance, Medical device, Pharma, Brexit, EU

The "European Post Marketing Pharmacovigilance - Including the EMA/PRAC Deliberations and Brexit Implications Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "European Post Marketing Pharmacovigilance - Including the EMA/PRAC Deliberations and Brexit Implications Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • This course provides a comprehensive overview of key post-market pharmacovigilance activities required as the foundation for further understanding of new EU legislation that was introduced in 2012 and has undergone over 20 updates in the last 10 years.
  • All of this is viewed from a practical point of view for compliance and Key Performance Indicators (KPIs).
  • The European Medicines Agency (EMA) and the Pharmacovigilance Risk Assessment Committee (PRAC) deliberations and Brexit implications will be discussed.

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022
Scrip, Allergan, National Stock Exchange, Growth, Piramal Group, The Carlyle Group, BSE, Ophthalmology, Contract, Inhalation, Pain management, PPL, Investment, Stock, McNeil Consumer Healthcare, NSE, Integrated services, PPS, CDMO, PEL, Board, CEO, OTC, Medication, Anesthetic, Financial services, Spasticity, PCC, Bombay Stock Exchange, Solution, Pharmaceutical industry, Fine chemical, Pharma

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022
Scrip, Allergan, National Stock Exchange, Growth, Piramal Group, The Carlyle Group, BSE, Ophthalmology, Contract, Inhalation, Pain management, PPL, Investment, Stock, McNeil Consumer Healthcare, NSE, Integrated services, PPS, CDMO, PEL, Board, CEO, OTC, Medication, Anesthetic, Financial services, Spasticity, PCC, Bombay Stock Exchange, Solution, Pharmaceutical industry, Fine chemical, Pharma

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Pharma, COPD, Pandemic, Growth, Annual report, Asthma, Research, Security (finance), Cystic fibrosis, Company, Degenerative disease, Lists of disasters, Oxford, Maintenance, COVID-19, Solution, Consultant, Pharmaceutical industry

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • Ensifentrine met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function.
  • Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide.
  • For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets.

Efficacy Testing Global Industry Report 2022: Growing Preference for Outsourcing Efficacy Testing to Drive Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 18, 2022
Science, Health, Other Science, Other Health, Adoption, Time, Use, Government, Growth, Laboratory, Final good, CAGR, Cosmetics, Cosmetic industry, Region, Awareness, Incidence, Conditional sentence, ADC, Medical device, Microbiology, USD, Contamination control, Personal care, Pharmaceutical industry, Pharma, Arbutus Biopharma

The "Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period.
  • The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach.
  • The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

Global Cellulose Nanofibers Market Research Report 2022-2032: Opportunities, Regulations and Standards, Supply Chain, Pricing, Key Markets, Company Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, October 17, 2022
Chemicals, Plastics, Manufacturing, Textiles, Cellulose, Growth, Hygiene, Daicel, CNF, Cosmetics, 3D, List of building materials, Nippon Paper Industries, Food additive, Deodorant, Flexible, Paint, Medication, Positive economics, Nanocomposite, Steel, Biopolymer, InterNetNews, Thermoplastic, Pulp (paper), Pharma, Health care, Aerogel, Filtration, Electronics, Biomedicine, Textile

The "The Global Market for Cellulose Nanofibers 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Market for Cellulose Nanofibers 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • They are also lightweight and have made a recent impact in industrial applications in biopolymers, bio-composites and hygiene and sanitary products.
  • Industrial products have been introduced to the market recently in packaging, composites and thermoplastics, biomedicine and hygiene, mainly in the Japanese market.
  • 1.4 Global production of nanocellulose (cellulose nanofibers, microfibrillated cellulose and cellulose nanocrystals)
    1.4.1 Global nanocellulose production capacities 2021, by type
    1.4.2 Cellulose nanofibers (CNF) production capacities 2022, in metric tonnes by producer

Syntegra and the Institute for Health Metrics Expand Strategic Partnership to Bring Privacy-Guaranteed Healthcare Data to Life Sciences

Retrieved on: 
Tuesday, October 18, 2022
SAN, LinkedIn, Institute for Health Metrics and Evaluation, Pharma, Risk, Population, Housing, PHI, RWD, COO, Patient, Privacy, HIPAA, Twitter, Institute, Partnership, SM, Organization, IHM, Industry, CEO, Synthetic data, Food, RWE, EHR, Health information management, Pharmaceutical industry, Medical imaging, Syntegra

This strategic partnership combines the privacy-preserving capabilities of Syntegra's synthetic data engine with IHM's vast data repository to provide access to high-fidelity, patient-level data that would not otherwise be available.

Key Points: 
  • This strategic partnership combines the privacy-preserving capabilities of Syntegra's synthetic data engine with IHM's vast data repository to provide access to high-fidelity, patient-level data that would not otherwise be available.
  • Organizations can access more granular data, and share it more broadly without the privacy risk of protected health information.
  • This unprecedented level of data access enables the life sciences industry to drive innovation and accelerate the development of new treatments for patients.
  • Notably, this data also includes social determinants of health variables (such as housing and food insecurity), as well as date-time stamps.

ValGenesis Launches "VLMS Express", a Next-Generation Digital Validation Tool Built for Small and Midsize Life Sciences Companies

Retrieved on: 
Tuesday, October 18, 2022
SAN, Parenteral Drug Association, Pharma, Culture, PAT, Growth, Organization, U.S. FDA, Multimedia, Automation, GxP, Industry, CEO, PDA, Environment, Digital, CTO, FDA, Title 21 CFR Part 11, Solution, Engineering, Risk management, Cryptocurrency

SAN FRANCISCO, Oct. 18, 2022 /PRNewswire/ -- Continuing its vision to deliver enterprise-class digital validation technology to every life sciences organization, ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), announced the release of VLMS Express, a next-generation digital validation tool purpose-built for small and midsize life sciences companies.

Key Points: 
  • SAN FRANCISCO, Oct. 18, 2022 /PRNewswire/ -- Continuing its vision to deliver enterprise-class digital validation technology to every life sciences organization, ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), announced the release of VLMS Express, a next-generation digital validation tool purpose-built for small and midsize life sciences companies.
  • ValGenesis launched this market-first offering to enable life sciences companies to further their digital transformation efforts with lighter, streamlined solutions.
  • ValGenesis is pioneering a "validation as a service" concept for organizations that need to start small, deploy quickly, and scale without issues.
  • VLMS Express is designed for these startups and other small and midsize life sciences companies by enabling them to start fast and cost-effectively.